Investment Summary

Advanced Medical Solutions Group PLC, known as AMS, is a leading independent developer and manufacturer of innovative tissue-healing technologies, surgical sealants, adhesives and advanced wound care products. The company has built a defensible portfolio anchored in scientifically differentiated technologies, supported by long-term relationships with global medical device partners and a growing direct branded presence. The combination of organic innovation, geographic expansion, accretive acquisitions, strong margins and a robust Balance Sheet positions AMS to deliver attractive long-term value creation. We rate the shares a Buy on the back of a strong commercial Franchise, expanding addressable market, healthy free Cash Flow conversion and a reasonable valuation that does not yet capture the company's full multi-year potential.

Business Overview

AMS is headquartered in Winsford, United Kingdom, with Manufacturing operations in the UK, Czech Republic, Germany, Netherlands, Italy and the United States. The company is listed on the London Stock Exchange AIM market. AMS operates two strategic business units. The Surgical division develops, manufactures and sells tissue-healing technologies including LiquiBand cyanoacrylate-based skin closure adhesives, LiquiBand Fix8 hernia mesh fixation devices, RESORBA absorbable sutures and haemostats, ifabond surgical adhesives, and proprietary internal sealants used during surgery. The Woundcare division supplies a broad range of advanced wound care products including silver alginate dressings, foam dressings, films and superabsorbents, marketed under both AMS-branded and OEM-partnered offerings.

The customer base spans hospitals, surgical centres, retail pharmacy chains, OEM device partners and distributors across more than 80 countries. Major branded products are sold through direct sales channels in Europe and the United States, while OEM partnerships extend reach across additional geographies. The combination of branded and OEM business provides a diversified Revenue model that balances growth potential with stable, recurring contributions.

Sector Backdrop

The global market for tissue-healing technologies, surgical adhesives, advanced wound care and haemostats is supported by several long-term drivers. Surgical volumes continue to grow with ageing populations and expanding healthcare access. Hospitals and surgical centres increasingly value minimally invasive techniques, faster recovery times and reduced complications, all of which are supported by advanced surgical adhesives, mesh fixation devices, sealants and haemostats. The advanced wound care market is supported by the rising prevalence of chronic wounds, diabetic foot ulcers, pressure injuries and surgical wounds. New technologies, including antimicrobial dressings, bioactive products and intelligent wound monitoring solutions, expand the addressable market and command premium pricing. Regulatory frameworks favour established players with strong quality systems, clinical evidence and regulatory expertise. Across these dynamics, AMS is well positioned with differentiated technology, a robust commercial footprint and ongoing innovation pipeline.

Investment Thesis

Our positive view on AMS rests on several elements. First, the company has built a portfolio of scientifically differentiated technologies, particularly in tissue adhesives and absorbable haemostats, that are protected by patents, regulatory clearances and proprietary manufacturing know-how. Second, the dual business model combining branded direct sales with OEM partnerships provides both growth and stability. Third, geographic expansion, particularly in the United States, Germany and emerging markets, continues to expand the addressable market. Fourth, recent acquisitions including Connexicon Medical (cyanoacrylate adhesives), Biomatlante (orthobiologics) and Syntacoll (collagen-based haemostats) have broadened the technology portfolio and added growth optionality. Fifth, financial performance is robust, with healthy margins, strong cash conversion and a Debt-light balance sheet that supports continued investment and M&A. Sixth, the valuation, while reflecting the company's quality, remains reasonable relative to specialised medical device peers and does not fully capture the cross-sell opportunity, US growth potential or pipeline contribution. The combination of these factors provides a balanced framework for medium-term outperformance.

Growth Drivers

Multiple specific growth drivers reinforce the medium-term outlook. LiquiBand continues to gain share in the global wound closure adhesive market, particularly in the United States, where the Brand has been steadily building a position against established competitors. Direct field force expansion, KOL engagement and clinical evidence generation have supported this commercial momentum. LiquiBand Fix8 is gaining traction in hernia mesh fixation, a procedure performed many millions of times globally each year, providing a defined growth runway as surgeon adoption builds. The RESORBA brand of absorbable sutures and haemostats, headquartered in Germany, provides strong European market positioning and is being expanded into the United States and additional geographies.

Internal surgical adhesives represent a transformational opportunity. AMS has been investing in the development of internal cyanoacrylate adhesives for applications in vascular surgery, gastrointestinal surgery and other internal indications. Internal adhesives address large addressable markets and command premium pricing. Successful clinical development, regulatory approval and commercial launch of these products could materially expand the addressable opportunity for the Surgical division. The advanced wound care business continues to benefit from new product launches across silver alginates, foams and bioactive technologies, supported by both branded and OEM channels.

Financial Performance

AMS has delivered a long track record of revenue and Earnings growth, supported by organic activity expansion, disciplined M&A and a focus on operational excellence. Reported revenues have grown at attractive single-digit to low double-digit rates over recent years, complemented by selective acquisitions. Gross margins remain strong, in the high 50s to low 60s percent range, reflecting the differentiated nature of the technology portfolio. Adjusted EBITDA margins are typically in the mid 20s percent range, with Operating Leverage supporting Margin expansion as revenue scales. Free cash flow conversion is consistently strong, supporting both reinvestment and selective M&A. The balance sheet remains conservative, with a healthy net cash position providing flexibility for value-creating acquisitions or Capital returns. Medium-term financial targets reflect continued top-line growth, margin discipline and strong cash generation.

Innovation and Pipeline Outlook

Innovation is at the heart of AMS's strategic framework. R&D investment has been increasing in absolute terms, supporting development across the Surgical and Woundcare divisions. Within Surgical, the pipeline includes next-generation internal cyanoacrylate adhesives, advanced haemostatic technologies leveraging collagen and oxidised regenerated cellulose, new mesh fixation devices and orthobiologic applications building on the Biomatlante Acquisition. Within Woundcare, the pipeline includes advanced foam dressings, super-absorbent technologies, antimicrobial products and bioactive offerings. Clinical evidence generation, including randomised controlled trials, comparative studies and real-world evidence programmes, supports product positioning and reimbursement. Partnerships with academic institutions, contract research organisations and clinical centres provide collaboration depth and scientific credibility. The combination of internal development, technology platforms acquired through M&A and partnerships supports a steady flow of new product introductions across multiple years.

Commercialisation Outlook

AMS's commercialisation model is tailored to the needs of each business unit and geography. In the Surgical division, direct field forces operate in the United Kingdom, United States, Germany and selected European markets, supporting LiquiBand, RESORBA and internal sealants. OEM partnerships with global medical device companies extend reach across additional geographies and product categories, providing scale efficiency. Distributor partnerships support sales into countries where direct presence would not be economical. In the Woundcare division, OEM partnerships with leading global wound care companies provide reach across hundreds of countries, complemented by branded direct sales and retail channels in select markets. The combination of channels provides both scale and growth, while balancing direct relationship investment with capital-light distribution efficiency.

Strategic Acquisitions and M&A

AMS has an established track record of disciplined, value-accretive M&A. Recent acquisitions including Connexicon Medical, Biomatlante and Syntacoll have expanded the technology portfolio with cyanoacrylate adhesives, orthobiologic products and collagen-based haemostats respectively. These acquisitions have been thoughtfully integrated, with revenue synergies emerging from cross-channel commercialisation, manufacturing efficiencies and combined R&D capabilities. The company maintains a clear acquisition strategy focused on technology-enabled medical products, with conservative valuation discipline and a focus on integration capability. The net cash balance sheet position provides ongoing capacity to pursue additional value-creating acquisitions. Future M&A opportunities include bolt-on additions in adhesives, haemostats, orthobiologics, surgical instruments and adjacent wound care technologies.

Dividend and Capital Returns

AMS maintains a progressive dividend policy, with the distribution comfortably covered by adjusted earnings and free cash flow. The dividend has grown steadily over many years. Special dividends have been used periodically to return surplus capital when value-creating M&A opportunities have not been available within target timeframes. Capital allocation priorities are reinvestment in R&D, selective M&A, organic commercial expansion and progressive dividend growth. The strong balance sheet provides flexibility to pursue additional capital return mechanisms if circumstances support it.

Valuation Perspective

AMS trades on a valuation that reflects its quality, growth and balance sheet strength. Forward earnings multiples are reasonable relative to specialised medical device peers, and EV/EBITDA metrics support an attractive entry point given the underlying growth profile. Discounted cash flow analysis incorporating conservative growth and margin assumptions points to meaningful upside from current levels. As US commercial expansion continues, internal adhesives progress through development and recent acquisitions deliver synergies, the financial profile is expected to strengthen further, supporting potential re-rating of the multiple.

Key Risks

Risks include hospital purchasing cycles, competitive intensity from established medical device companies, regulatory and reimbursement developments affecting surgical adhesives, advanced wound care and haemostats, foreign exchange Volatility given international revenue exposure, integration risk on acquisitions, manufacturing reliability and Supply chain stability. Clinical trial outcomes for internal adhesives programmes and regulatory approval pathways introduce some uncertainty. Macro factors including hospital capital spending cycles, healthcare budget pressures and emerging market currency volatility also need to be monitored.

Sustainability and ESG

AMS emphasises sustainability across its operations, supply chain and product portfolio. Commitments include reducing greenhouse gas emissions, optimising water use, minimising waste and developing more sustainable packaging. The company supports clinical professionals through education programmes and patient outcomes through clinical evidence generation. Strong governance, ethical compliance and stakeholder engagement support broader sustainability positioning. The mission of supporting better surgical outcomes and wound healing aligns with broader healthcare system goals.

US Market Opportunity and Strategic Priority

The United States represents the single most important growth opportunity for AMS. As the largest medical device market in the world, the US offers significant revenue potential across the company's surgical adhesives, haemostats and sealants portfolio. AMS has been steadily building its US commercial presence, with direct sales teams covering LiquiBand wound closure adhesive across emergency departments, urgent care centres, primary care practices and surgical centres. The recent expansion of the US sales force, addition of new key account managers, KOL engagement programmes and targeted Marketing initiatives are supporting accelerated US revenue growth. Beyond LiquiBand, opportunities exist to expand the US presence across LiquiBand Fix8 in hernia surgery, RESORBA absorbable haemostats in surgical applications and selected advanced wound care products. Continued US growth is expected to be a primary engine of overall revenue expansion over the medium term.

The competitive landscape in the United States is dominated by large multinational medical device companies, but AMS has been demonstrating the ability to compete effectively through differentiated products, focused commercial efforts and Customer Service. Continued investment in clinical evidence, regulatory clearances for new indications and KOL relationships supports the company's positioning. Partnerships with US distributors, group purchasing organisations and integrated delivery networks expand reach. While the path to US market leadership requires sustained investment over multiple years, the underlying scale of the opportunity and the demonstrated competitiveness of the product portfolio support our confidence in the strategy.

Conclusion: Why We Rate AMS a Buy

Advanced Medical Solutions Group PLC offers attractive exposure to the structural growth of surgical adhesives, haemostats, sealants and advanced wound care through a portfolio of differentiated technologies, a diversified commercial model and a disciplined operational and financial framework. With continued investment in innovation, geographic expansion, accretive M&A and ongoing operating leverage, the company is well placed to deliver sustained earnings growth and total returns. We therefore rate Advanced Medical Solutions Group PLC a Buy, viewing the shares as a high-quality way to invest in the Long-term Growth of tissue-healing technologies and advanced wound care.